Trials / Completed
CompletedNCT02753309
A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
A Randomized Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is looking at the effects of Sirolimus (Rapamycin) on BCG-specific immunity during treatment of non-muscle invasive bladder cancer (NMIBC) with maintenance BCG.
Detailed description
This study will evaluate change from baseline in gamma-delta T cell numbers and function and Ag85 peptide-specific T cell responses following treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sirolimus |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2019-12-01
- Completion
- 2021-03-02
- First posted
- 2016-04-27
- Last updated
- 2021-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02753309. Inclusion in this directory is not an endorsement.